Im­mune Reg­u­la­tion, tak­ing two clin­i­cal pro­grams to 're­set' the im­mune sys­tem, nets $53M+ Se­ries B

A lit­tle un­der two years af­ter a com­pa­ny re­brand­ing, Im­mune Reg­u­la­tion is tak­ing an even big­ger step to­ward ad­vanc­ing its goals.

For­mer­ly known as Peptin­no­vate, the British biotech an­nounced a $53.4 mil­lion Se­ries B ear­ly Mon­day morn­ing, help­ing to fur­ther ad­vance two clin­i­cal pro­grams in rheuma­toid arthri­tis and asth­ma. Though those are the two ini­tial in­di­ca­tions the com­pa­ny is fo­cus­ing on, CEO Jonathan Rig­by told End­points News he hopes the can­di­dates can be ap­plied to a broad swath of au­toim­mune dis­or­ders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER